Share Name | Share Symbol | Market | Type |
---|---|---|---|
DNAPrint Genomics Inc (CE) | USOTC:DNAG | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.00 | 00:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D. C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934.
February 1, 2008
Date of Report (Date of Earliest Event Reported)
|
DNAPrint Genomics, Inc. |
|
|
(Exact name of registrant as specified in charter) |
|
Utah |
|
0-31905 |
|
59-2780520 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
1621 West University Parkway, Sarasota, FL 34243 |
|
|
(Address of principal executive offices) |
|
|
(941) 366-3400 |
|
|
(Registrant’s Telephone Number, including Area Code) |
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01
OTHER EVENTS
On January 18, 2008, the Registrant entered into a nonbinding letter of intent with Nanobac Pharmaceuticals, Incorporated (“Nanobac”). This letter of intent was amended on February 1, 2008. This letter of intent and amendment are filed with this 8-K.
ITEM 9.01
EXHIBITS
99.01 Non-binding letter of intent dated January 18, 2008 between Nanobac Pharmaceuticals, Incorporated and the Registrant.
99.02 Amendment dated February 1, 2008 to the non-binding letter of intent between Nanobac Pharmaceuticals, Incorporate and the Registrant.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
DNAPrint Genomics, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Richard Gabriel |
|
|
|
|
Richard Gabriel |
|
|
|
|
Chief Executive Officer & President |
1 Year DNAPrint Genomics (CE) Chart |
1 Month DNAPrint Genomics (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions